Pramlintide

Classification

Amylin analogue

Approval status

Approved medicine

Research status

Labelled indications are defined in product information.

Molecular formula

Insufficient reliable evidence identified.

Molecular weight

Insufficient reliable evidence identified.

Sequence

Synthetic analogue of human amylin (islet amyloid polypeptide).

Primary biological target

Amylin receptors (calcitonin-receptor complexes)

Half-life

Insufficient reliable evidence identified.

Routes investigated

Subcutaneous

Human evidence level

A — Approved clinical use / strong human evidence

An approved adjunct peptide injection for selected insulin-treated diabetes, as labelled.

Established (labelled / textbook receptor pharmacology)

Amylin-receptor agonism slows gastric emptying, suppresses post-prandial glucagon and promotes satiety.

Reduces post-prandial glucose excursions when used as labelled with insulin — hypoglycaemia risk requires insulin down-titration per PI.

• Type 1 diabetes adjunct
• Insulin-treated type 2 diabetes

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Overall human evidence grade: A · Approved clinical use / strong human evidence

Labelled clinical programme for Symlin.

Animal, cell and in-vitro findings are listed separately from human effects.

Amylin physiology is established.

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Nausea; severe hypoglycaemia when insulin is not reduced as labelled.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Gastroparesis, hypoglycaemia unawareness — see PI.

FDA-approved (Symlin). Confirm other agencies.

Verify ARTG; not sold here.

1. [1] Symlin (pramlintide) prescribing information

   Symlin (pramlintide) prescribing information

   Open source